ritanserin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Ritanserin, also known by its developmental code name R-55667, is a serotonin antagonist medication described as an anxiolytic, antidepressant, antiparkinsonian agent, and antihypertensive agent. It was chiefly investigated as a drug to treat insomnia, especially to enhance sleep quality by significantly increasing slow wave sleep by virtue of potent and concomitant 5HT2a and 5HT2c antagonism   Wikipedia

Chemistry

  • SMILES: CC1=C(CCN2CCC(=C(c3ccc(F)cc3)c4ccc(F)cc4)CC2)C(=O)N5C=CSC5=N1
  • InChIKey: JUQLTPCYUFPYKE-UHFFFAOYSA-N
  • Mol. Mass: 477.58
  • ALogP: 5.48
  • ChEMBL Molecule:
    ritanserin  
More Chemistry

Pharmacology

Alternative names

r-55667 | ritanserin | tiserton

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Cocaine-Related Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue